RADIANCE Continued Access Protocol (RADIANCE CAP)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05017935 |
Recruitment Status :
Active, not recruiting
First Posted : August 24, 2021
Last Update Posted : March 4, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hypertension Hypertension, Resistant to Conventional Therapy Vascular Diseases Cardiovascular Diseases | Device: Renal Denervation | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 300 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | RADIANCE Continued Access Protocol (RADIANCE CAP): A Study of the ReCor Medical Paradise System in Clinical Hypertension |
Actual Study Start Date : | May 4, 2022 |
Estimated Primary Completion Date : | December 31, 2028 |
Estimated Study Completion Date : | December 31, 2028 |
Arm | Intervention/treatment |
---|---|
Experimental: Renal Denervation |
Device: Renal Denervation
Renal angiogram and renal denervation (Paradise ultrasound Renal Denervation System) |
- Incidence of Adverse Events [ Time Frame: From baseline to 60 months ]
- Change in average daytime ambulatory systolic BP [ Time Frame: From baseline to 2 months post procedure ]
- Change in average 24-hr/night-time ambulatory systolic BP [ Time Frame: From baseline to 2 months post procedure ]
- Change in average daytime/24-hr/night-time ambulatory systolic BP [ Time Frame: From Baseline to Months 6 and 12 post procedure ]
- Change in average office systolic/diastolic BP [ Time Frame: From Baseline to Months 2, 6, 12, 24, 36, 48, and 60 post procedure ]
- Change in average home systolic/diastolic BP [ Time Frame: From Baseline to Months 2, 6, 12, 24, 36, 48, and 60 post procedure ]
- Change in average 24-hr/night-time ambulatory diastolic BP [ Time Frame: From baseline to Months 2, 6, and 12 post procedure ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Average office BP ≥140/90 mmHg at screening visit despite taking stables doses of antihypertensive medications for at least 4 weeks prior to consent
- Documented daytime ABP ≥135/85 mmHg following 4 week run-in/standardization period on antihypertensive medication regimen
Exclusion Criteria:
- Renal artery anatomy ineligible for treatment
- Secondary hypertension not including sleep apnea
- Type I diabetes mellitus or uncontrolled Type II diabetes (defined as plasma HbA1c ≥9.0%)
- eGFR <40
- Brachial circumference ≥42 cm
- Any history of cerebrovascular event or severe cardiovascular event within 3 months prior to consent
- Documented repeat (>1) hospitalization for hypertensive crisis within 3 months prior to consent
- Documented confirmed episode(s) of unstable angina within 3 months prior to consent
- Chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea
- Primary pulmonary hypertension
- Night shift workers
- Pregnant, nursing or planning to become pregnant
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05017935
Principal Investigator: | Naomi Fisher, MD | Brigham and Women's Hospital/Harvard Medical School | |
Principal Investigator: | Ajay Kirtane, MD, SM | Columbia University Medical Center/NYPH |
Publications:
Responsible Party: | ReCor Medical, Inc. |
ClinicalTrials.gov Identifier: | NCT05017935 |
Other Study ID Numbers: |
CLN-0932 |
First Posted: | August 24, 2021 Key Record Dates |
Last Update Posted: | March 4, 2024 |
Last Verified: | February 2024 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Device Product Not Approved or Cleared by U.S. FDA: | Yes |
Blood Pressure Uncontrolled Hypertension Essential Hypertension Resistant Hypertension Denervation |
Hypertension Cardiovascular Diseases Vascular Diseases |